

ID No.	K1004
Project Title	Clinical development of cord blood derived virus-specific T cell therapy for cord blood transplant recipients in Japan
Principal Investigator	Catherine M. Bollard (Director, Prof./Center for Cancer & Immunology, Children's National Medical Center)
Project Members IMSUT Host Researcher Members	Satoshi Takahashi (Associate Prof./IMSUT)  Patrick J. Hanley (GMP Facility Director/Center for Cancer & Immunology, Children's National Medical Center)  Satoshi Yamazaki (Associate Prof./IMSUT and Tsukuba Univ.)
Report	
<p>CB-VST studies has been extended in the studies of Dr. Bollard and her team as shown following publications:</p> <p>Abraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, <u>Hanley PJ</u>, <u>Bollard CM</u>. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019 Jul 23;3(14):2057-2068. doi: 10.1182/bloodadvances.2019000201.</p> <p>Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, <u>Hanley PJ</u>, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, <u>Bollard CM</u>. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019 Oct;187(2):206-218. doi: 10.1111/bjh.16053. Epub 2019 Jun 20.</p> <p>Keller MD, <u>Bollard CM</u>. Virus-specific T-cell therapies for patients with primary immune deficiency. Blood. 2020 Feb 27;135(9):620-628. doi: 10.1182/blood.2019000924.</p> <p>We have discussed by email and online meeting how to combine the VST production and hematopoietic stem cell expansion from same cord blood unit using for transplantation in clinic.</p>	